Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Huntington's: Long-Term drug trial underway

NCT ID NCT06254482

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the long-term safety and effects of the drug votoplam in people with Huntington's disease. About 144 participants who finished a previous votoplam study will take part. The goal is to see how the drug affects Huntington's protein levels and brain changes over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Huntington disease neurodegenerative disease Rare Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUNTINGTON DISEASE

Contacts and locations

Locations

  • Novartis Investigative Site

    Clayton, 3168, Australia

  • Novartis Investigative Site

    Westmead, 2145, Australia

  • Novartis Investigative Site

    Innsbruck, 6020, Austria

  • Novartis Investigative Site

    Ottawa, K1Y 4E9, Canada

  • Novartis Investigative Site

    Angers, 49100, France

  • Novartis Investigative Site

    Marseille, 13385, France

  • Novartis Investigative Site

    Paris, 75013, France

  • Novartis Investigative Site

    Berlin, 10117, Germany

  • Novartis Investigative Site

    Bochum, 44791, Germany

  • Novartis Investigative Site

    Münster, 48149, Germany

  • Novartis Investigative Site

    Ulm, 89081, Germany

  • Novartis Investigative Site

    Bologna, 40139, Italy

  • Novartis Investigative Site

    Milan, 20133, Italy

  • Novartis Investigative Site

    San Giovanni Rotondo, 71013, Italy

  • Novartis Investigative Site

    Leiden, 2333 ZA, Netherlands

  • Novartis Investigative Site

    Christchurch, 8011, New Zealand

  • Novartis Investigative Site

    Barakaldo, 48903, Spain

  • Novartis Investigative Site

    Barcelona, 8025, Spain

  • Novartis Investigative Site

    Burgos, 90550, Spain

  • Novartis Investigative Site

    Madrid, 28034, Spain

  • Novartis Investigative Site

    Birmingham, B15 2FG, United Kingdom

  • Novartis Investigative Site

    Cardiff, CF14 4XW, United Kingdom

  • Novartis Investigative Site

    London, WC1N 3BG, United Kingdom

  • Novartis Investigative Site

    Manchester, M13 9WL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.